An organizational restructuring and commercialization initiative involving the transfer of multimodal AI products and services in the health and medical fields to wholly owned subsidiary ExaMD, followed by their rollout using business assets in dementia, frailty, SaMD, and industry-academia and pharmaceutical joint research.